"\u0410\u0432\u0430\u043D\u0430\u0444\u0438\u043B \u2014 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0438\u0437 \u0444\u0430\u0440\u043C\u0430\u043A\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u043E\u0439 \u0433\u0440\u0443\u043F\u043F\u044B \u0424\u0414\u042D-5 \u0438\u043D\u0433\u0438\u0431\u0438\u0442\u043E\u0440\u043E\u0432, \u043F\u0440\u0435\u0434\u043D\u0430\u0437\u043D\u0430\u0447\u0435\u043D\u043D\u044B\u0439 \u0434\u043B\u044F \u043B\u0435\u0447\u0435\u043D\u0438\u044F \u044D\u0440\u0435\u043A\u0442\u0438\u043B\u044C\u043D\u043E\u0439 \u0434\u0438\u0441\u0444\u0443\u043D\u043A\u0446\u0438\u0438. \u041F\u043E\u043B\u0443\u0447\u0438\u043B \u043E\u0434\u043E\u0431\u0440\u0435\u043D\u0438\u0435 \u043E\u0442 FDA \u0432 2012 \u0433\u043E\u0434\u0443. \u0410\u0432\u0430\u043D\u0430\u0444\u0438\u043B \u0438\u0437\u0432\u0435\u0441\u0442\u0435\u043D \u043F\u043E\u0434 \u0442\u043E\u0432\u0430\u0440\u043D\u044B\u043C\u0438 \u0437\u043D\u0430\u043A\u0430\u043C\u0438 Stendra \u0438 Spedra, \u043E\u043D \u0431\u044B\u043B \u0440\u0430\u0437\u0440\u0430\u0431\u043E\u0442\u0430\u043D \u043A\u043E\u043C\u043F\u0430\u043D\u0438\u0435\u0439 VIVUS Inc. \u0412 \u0438\u044E\u043B\u0435 2013 \u0433\u043E\u0434\u0430 Vivus \u043E\u0431\u044A\u044F\u0432\u0438\u043B\u0430 \u043E \u0442\u043E\u043C, \u0447\u0442\u043E \u0432 \u043F\u0430\u0440\u0442\u043D\u0451\u0440\u0441\u0442\u0432\u0435 \u0441 Menarini Group \u0431\u0443\u0434\u0435\u0442 \u0441\u043F\u043E\u0441\u043E\u0431\u0441\u0442\u0432\u043E\u0432\u0430\u0442\u044C \u043F\u0440\u043E\u0434\u0432\u0438\u0436\u0435\u043D\u0438\u044E \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430 \u043F\u043E\u0434 \u043C\u0430\u0440\u043A\u043E\u0439 Stendra \u0432 \u0431\u043E\u043B\u0435\u0435 \u0447\u0435\u043C 40 \u0441\u0442\u0440\u0430\u043D\u0430\u0445 \u0415\u0432\u0440\u043E\u043F\u044B, \u0430 \u0442\u0430\u043A\u0436\u0435 \u0432 \u0410\u0432\u0441\u0442\u0440\u0430\u043B\u0438\u0438 \u0438 \u041D\u043E\u0432\u043E\u0439 \u0417\u0435\u043B\u0430\u043D\u0434\u0438\u0438."@ru . . "7649"^^ . . . . . . "D03217" . . . . . . "WEAJZXNPAWBCOA-INIZCTEOSA-N"@en . . "Clc1ccccCNc3ncN4[C@@H]CO"@en . . . "1"^^ . . . . . "1963681" . . "Avanafil"@pt . . . . "\u0410\u0432\u0430\u043D\u0430\u0444\u0438\u043B"@ru . "DB06237" . "\u0410\u0432\u0430\u043D\u0430\u0444\u0438\u043B \u2014 \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442 \u0438\u0437 \u0444\u0430\u0440\u043C\u0430\u043A\u043E\u043B\u043E\u0433\u0438\u0447\u0435\u0441\u043A\u043E\u0439 \u0433\u0440\u0443\u043F\u043F\u044B \u0424\u0414\u042D-5 \u0438\u043D\u0433\u0438\u0431\u0438\u0442\u043E\u0440\u043E\u0432, \u043F\u0440\u0435\u0434\u043D\u0430\u0437\u043D\u0430\u0447\u0435\u043D\u043D\u044B\u0439 \u0434\u043B\u044F \u043B\u0435\u0447\u0435\u043D\u0438\u044F \u044D\u0440\u0435\u043A\u0442\u0438\u043B\u044C\u043D\u043E\u0439 \u0434\u0438\u0441\u0444\u0443\u043D\u043A\u0446\u0438\u0438. \u041F\u043E\u043B\u0443\u0447\u0438\u043B \u043E\u0434\u043E\u0431\u0440\u0435\u043D\u0438\u0435 \u043E\u0442 FDA \u0432 2012 \u0433\u043E\u0434\u0443. \u0410\u0432\u0430\u043D\u0430\u0444\u0438\u043B \u0438\u0437\u0432\u0435\u0441\u0442\u0435\u043D \u043F\u043E\u0434 \u0442\u043E\u0432\u0430\u0440\u043D\u044B\u043C\u0438 \u0437\u043D\u0430\u043A\u0430\u043C\u0438 Stendra \u0438 Spedra, \u043E\u043D \u0431\u044B\u043B \u0440\u0430\u0437\u0440\u0430\u0431\u043E\u0442\u0430\u043D \u043A\u043E\u043C\u043F\u0430\u043D\u0438\u0435\u0439 VIVUS Inc. \u0412 \u0438\u044E\u043B\u0435 2013 \u0433\u043E\u0434\u0430 Vivus \u043E\u0431\u044A\u044F\u0432\u0438\u043B\u0430 \u043E \u0442\u043E\u043C, \u0447\u0442\u043E \u0432 \u043F\u0430\u0440\u0442\u043D\u0451\u0440\u0441\u0442\u0432\u0435 \u0441 Menarini Group \u0431\u0443\u0434\u0435\u0442 \u0441\u043F\u043E\u0441\u043E\u0431\u0441\u0442\u0432\u043E\u0432\u0430\u0442\u044C \u043F\u0440\u043E\u0434\u0432\u0438\u0436\u0435\u043D\u0438\u044E \u043F\u0440\u0435\u043F\u0430\u0440\u0430\u0442\u0430 \u043F\u043E\u0434 \u043C\u0430\u0440\u043A\u043E\u0439 Stendra \u0432 \u0431\u043E\u043B\u0435\u0435 \u0447\u0435\u043C 40 \u0441\u0442\u0440\u0430\u043D\u0430\u0445 \u0415\u0432\u0440\u043E\u043F\u044B, \u0430 \u0442\u0430\u043A\u0436\u0435 \u0432 \u0410\u0432\u0441\u0442\u0440\u0430\u043B\u0438\u0438 \u0438 \u041D\u043E\u0432\u043E\u0439 \u0417\u0435\u043B\u0430\u043D\u0434\u0438\u0438."@ru . . "Avanafil"@en . . . . "Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is sold under the brand names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co., and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand. Metuchen Pharmaceuticals obtained exclusive rights within the United States. Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme found in various body tissues, primarily in the corpus cavernosum penis. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum serum concentration in about thirty to forty-five minutes. About two-thirds of the participants were able to engage in sexual activity within fifteen minutes."@en . . . . . "\u0623\u0641\u0627\u0646\u0627\u0641\u064A\u0644 \u0648\u064A\u0639\u0631\u0641 \u0628\u0627\u0644\u0627\u0633\u0645 \u0627\u0644\u062A\u062C\u0627\u0631\u064A \u0623\u0641\u0627\u0646\u0627\u0641\u064A\u0644 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Avanafil)\u200F \u0647\u0648 \u062F\u0648\u0627\u0621 \u0644\u0639\u0644\u0627\u062C \u062D\u0627\u0644\u0627\u062A \u0627\u0644\u0636\u0639\u0641 \u0623\u0648 \u0627\u0644\u0639\u062C\u0632 \u0627\u0644\u062C\u0646\u0633\u064A \u0644\u062F\u0649 \u0627\u0644\u0631\u062C\u0627\u0644."@ar . . . "changed"@en . . . . "Avanafil \u00E4r en PDE5-h\u00E4mmare som anv\u00E4nds mot erektil dysfunktion (ED). Det \u00E4r den aktiva substansen i l\u00E4kemedlen Spedra och Stendra. Avanafil verkar p\u00E5 ett liknande s\u00E4tt som de andra PDE5-h\u00E4mmarna sildenafil, vardenafil och tadalafil. Avanafil absorberas snabbt och verkar ofta inom 15 minuter. L\u00E4kemedlet n\u00E5r vanligtvis full effekt inom 30 till 45 minuter. Biverkningar uppst\u00E5r i s\u00E4llsynta fall, bland annat yrsel, huvudv\u00E4rk, rodnad i ansiktet och f\u00F6rstoppning. Andra m\u00F6jliga biverkningar av avanafil inkluderar n\u00E4st\u00E4ppa, v\u00E4rmevallningar, ryggsm\u00E4rta, dimsyn, muntorrhet, muskelsp\u00E4nningar, tr\u00F6tthetssymtom, \u00F6kad hj\u00E4rtfrekvens, svindel, diarr\u00E9, br\u00F6stsm\u00E4rta, blodblandad urin och h\u00F6gt blodtryck. Bland de mer allvarliga biverkningar som kan uppst\u00E5 vid anv\u00E4ndande av detta l\u00E4kemedel kan svullna \u00F6gonlock, tinnitus, pl\u00F6tslig f\u00F6rlust av h\u00F6rseln, pl\u00F6tslig f\u00F6rlust av synen p\u00E5 ena \u00F6gat eller b\u00E4gge \u00F6gonen, samt priapism (en l\u00E5ngvarig erektion som varar l\u00E4ngre \u00E4n 4 timmar) n\u00E4mnas. L\u00E4kemedlet godk\u00E4ndes av den europeiska l\u00E4kemedelsmyndigheten EMA den 21 juni 2013, och blev d\u00E4rmed den fj\u00E4rde PDE5-h\u00E4mmaren att sl\u00E4ppas p\u00E5 marknaden."@sv . "Avanafil ist ein Arzneistoff aus der Gruppe der PDE-5-Hemmer, der in der Behandlung der erektilen Dysfunktion eingesetzt wird."@de . . . . . . "Awanafil \u2013 organiczny zwi\u0105zek chemiczny b\u0119d\u0105cy wysoce selektywnym, silnym i odwracalnym inhibitorem typu 5 (PDE5), swoistej dla cyklicznego guanozynomonofosforanu (cGMP). W badaniach in vitro wykazano, \u017Ce awanafil jest silnie wybi\u00F3rczy w odniesieniu do PDE5, bardziej ni\u017C w odniesieniu do innych znanych fosfodiesteraz (>100-krotnie ni\u017C w przypadku PDE6; >1000-krotnie ni\u017C w przypadku PDE4, PDE8 i PDE10; >5000-krotnie ni\u017C w przypadku PDE2 i PDE7; >10 000-krotnie ni\u017C w przypadku PDE1, PDE3, PDE9, i PDE11). Substancja wykorzystywana jest w leczeniu zaburze\u0144 erekcji (ang. erectile dysfunction \u2013 ED) u m\u0119\u017Cczyzn. Awanafil wyst\u0119puje w postaci bia\u0142ego, krystalicznego proszku."@pl . "\u0623\u0641\u0627\u0646\u0627\u0641\u064A\u0644 \u0648\u064A\u0639\u0631\u0641 \u0628\u0627\u0644\u0627\u0633\u0645 \u0627\u0644\u062A\u062C\u0627\u0631\u064A \u0623\u0641\u0627\u0646\u0627\u0641\u064A\u0644 (\u0628\u0627\u0644\u0625\u0646\u062C\u0644\u064A\u0632\u064A\u0629: Avanafil)\u200F \u0647\u0648 \u062F\u0648\u0627\u0621 \u0644\u0639\u0644\u0627\u062C \u062D\u0627\u0644\u0627\u062A \u0627\u0644\u0636\u0639\u0641 \u0623\u0648 \u0627\u0644\u0639\u062C\u0632 \u0627\u0644\u062C\u0646\u0633\u064A \u0644\u062F\u0649 \u0627\u0644\u0631\u062C\u0627\u0644."@ar . . . . . . "12767889"^^ . "1120862818"^^ . "Awanafil"@pl . . "-4"^^ . "N"@en . "Avanafil ou Avanafila (nome comercial Stendra ou Spedra) \u00E9 um desevolvido para o tratamento da disfun\u00E7\u00E3o er\u00E9til. A propriet\u00E1ria da mol\u00E9cula \u00E9 o laborat\u00F3rio farmac\u00EAutico Vivus. Foi aprovado pelo FDA para comercializa\u00E7\u00E3o em 27 de abril de 2012."@pt . . "a614010"@en . . . . . . . . . . . . . . . . . . "1963681"^^ . . . . "Avanafil"@en . "3"^^ . . . "Avanafil"@fr . "8045620"^^ . . "Stendra"@en . . . . "D03217"@en . . "Rx-only"@en . "Avanafil ball-and-stick.png"@en . . . . "DR5S136IVO" . "BE10"@en . "447824430"^^ . . "26"^^ . . "Awanafil \u2013 organiczny zwi\u0105zek chemiczny b\u0119d\u0105cy wysoce selektywnym, silnym i odwracalnym inhibitorem typu 5 (PDE5), swoistej dla cyklicznego guanozynomonofosforanu (cGMP). W badaniach in vitro wykazano, \u017Ce awanafil jest silnie wybi\u00F3rczy w odniesieniu do PDE5, bardziej ni\u017C w odniesieniu do innych znanych fosfodiesteraz (>100-krotnie ni\u017C w przypadku PDE6; >1000-krotnie ni\u017C w przypadku PDE4, PDE8 i PDE10; >5000-krotnie ni\u017C w przypadku PDE2 i PDE7; >10 000-krotnie ni\u017C w przypadku PDE1, PDE3, PDE9, i PDE11). Substancja wykorzystywana jest w leczeniu zaburze\u0144 erekcji (ang. erectile dysfunction \u2013 ED) u m\u0119\u017Cczyzn. Awanafil wyst\u0119puje w postaci bia\u0142ego, krystalicznego proszku."@pl . . . . . . "7"^^ . . "Avanafil"@nl . . "9869929" . "Rx-only"@en . . "330784-47-9" . . . . "Avanafil (INN, merknaam Spedra of Stendra) is een geneesmiddel voor de behandeling van erectiestoornis bij volwassen mannen. Het is enkel effectief als het gepaard gaat met seksuele stimulatie. Avanafil is ontwikkeld door het farmaceutisch bedrijf Vivus met hoofdkwartier in Mountain View, Californi\u00EB. Er is nog geen ATC-code toegewezen aan avanafil. Het is op 21 juni 2013 toegelaten in de Europese Unie."@nl . . "Avanafil"@en . "Avanafil"@sv . "Avanafil \u00E4r en PDE5-h\u00E4mmare som anv\u00E4nds mot erektil dysfunktion (ED). Det \u00E4r den aktiva substansen i l\u00E4kemedlen Spedra och Stendra. Avanafil verkar p\u00E5 ett liknande s\u00E4tt som de andra PDE5-h\u00E4mmarna sildenafil, vardenafil och tadalafil. Avanafil absorberas snabbt och verkar ofta inom 15 minuter. L\u00E4kemedlet n\u00E5r vanligtvis full effekt inom 30 till 45 minuter. L\u00E4kemedlet godk\u00E4ndes av den europeiska l\u00E4kemedelsmyndigheten EMA den 21 juni 2013, och blev d\u00E4rmed den fj\u00E4rde PDE5-h\u00E4mmaren att sl\u00E4ppas p\u00E5 marknaden."@sv . "9869929"^^ . "Avanafil \u00E8 una molecola appartenente alla classe degli inibitori della PDE5. \u00C8 il quarto farmaco della classe approvato per la cura della disfunzione erettile dalla Food and Drug Administration. Il farmaco \u00E8 stato approvato il 27 aprile 2012 dalla FDA e il 21 giugno 2013 dalla European Medicines Agency.Avanafil si distingue da altri inibitori della PDE5 per una rapida insorgenza d'azione, circa 15 min.Negli Stati Uniti viene venduto con il nome commerciale di Stendra dalla societ\u00E0 farmacologica Vivus. Nel luglio 2013 Vivus ha annunciato un accordo di partnership con la societ\u00E0 farmaceutica Menarini per commercializzare e promuovere avanafil con il nome commerciale di Spedra in oltre 40 paesi europei, in Australia e Nuova Zelanda."@it . "L\u2019avanafil est un inhibiteur de la PDE-5 utilis\u00E9 pour le traitement de l\u2019impuissance sexuelle. L\u2019avanafil est connu sous le nom commercial Stendra (en France sous le nom de Spedra) et a \u00E9t\u00E9 d\u00E9velopp\u00E9 par Vivus Inc. L\u2019avantage de l\u2019avanafil est que le d\u00E9but de l\u2019action est tr\u00E8s rapide compar\u00E9 aux autres inhibiteurs de la phosphodiest\u00E9rase."@fr . . "E6L"@en . . "Avanafil is a PDE5 inhibitor"@en . "DR5S136IVO"@en . "L\u2019avanafil est un inhibiteur de la PDE-5 utilis\u00E9 pour le traitement de l\u2019impuissance sexuelle. L\u2019avanafil est connu sous le nom commercial Stendra (en France sous le nom de Spedra) et a \u00E9t\u00E9 d\u00E9velopp\u00E9 par Vivus Inc. L\u2019avantage de l\u2019avanafil est que le d\u00E9but de l\u2019action est tr\u00E8s rapide compar\u00E9 aux autres inhibiteurs de la phosphodiest\u00E9rase."@fr . "66876" . . "G04"@en . . . . "1"^^ . . . . "DB06237"@en . "Avanafil \u00E8 una molecola appartenente alla classe degli inibitori della PDE5. \u00C8 il quarto farmaco della classe approvato per la cura della disfunzione erettile dalla Food and Drug Administration. Il farmaco \u00E8 stato approvato il 27 aprile 2012 dalla FDA e il 21 giugno 2013 dalla European Medicines Agency.Avanafil si distingue da altri inibitori della PDE5 per una rapida insorgenza d'azione, circa 15 min.Negli Stati Uniti viene venduto con il nome commerciale di Stendra dalla societ\u00E0 farmacologica Vivus. Nel luglio 2013 Vivus ha annunciato un accordo di partnership con la societ\u00E0 farmaceutica Menarini per commercializzare e promuovere avanafil con il nome commerciale di Spedra in oltre 40 paesi europei, in Australia e Nuova Zelanda."@it . . . . . . . . . . . "POM"@en . . . . "Avanafil (INN, merknaam Spedra of Stendra) is een geneesmiddel voor de behandeling van erectiestoornis bij volwassen mannen. Het is enkel effectief als het gepaard gaat met seksuele stimulatie. Avanafil is ontwikkeld door het farmaceutisch bedrijf Vivus met hoofdkwartier in Mountain View, Californi\u00EB. Er is nog geen ATC-code toegewezen aan avanafil. Het is op 21 juni 2013 toegelaten in de Europese Unie."@nl . "Avanafil ou Avanafila (nome comercial Stendra ou Spedra) \u00E9 um desevolvido para o tratamento da disfun\u00E7\u00E3o er\u00E9til. A propriet\u00E1ria da mol\u00E9cula \u00E9 o laborat\u00F3rio farmac\u00EAutico Vivus. Foi aprovado pelo FDA para comercializa\u00E7\u00E3o em 27 de abril de 2012."@pt . "yes"@en . "Avanafil is a PDE5 inhibitor approved for erectile dysfunction by the FDA on April 27, 2012 and by EMA on June 21, 2013. Avanafil is sold under the brand names Stendra and Spedra. It was invented at Mitsubishi Tanabe Pharma, formerly known as Tanabe Seiyaku Co., and licensed to Vivus Inc., which partnered with Menarini Group to commercialise Spedra in over forty European countries, Australia, and New Zealand. Metuchen Pharmaceuticals obtained exclusive rights within the United States."@en . . . . . "66876"^^ . "changed"@en . "23"^^ . "330784"^^ . . . "Avanafil"@de . . "Avanafil"@it . . . "7448"^^ . "\u0623\u0641\u0627\u0646\u0627\u0641\u064A\u0644"@ar . . . "a614010" . "Avanafil ist ein Arzneistoff aus der Gruppe der PDE-5-Hemmer, der in der Behandlung der erektilen Dysfunktion eingesetzt wird."@de . . . "Stendra"@en . .